Cyclacel Pharmaceuticals IncNASDAQ:CYCCNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE1.0100
- TODAY'S CHANGE (%)0.0100 (1.0000%)
- Bid / Lots0.9900/ 10
- Ask / Lots1.0500/ 26
- Open / Previous Close1.0050 / 1.0000
- Day Range
- 52 Week Range
- Volume15,875
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | CYCC |
|---|---|---|
| 09:54 ET | 3111 | 1.0001 |
| 09:57 ET | 275 | 1 |
| 10:08 ET | 1000 | 1.03 |
| 10:21 ET | 667 | 1.02 |
| 10:46 ET | 1015 | 1.02 |
| 10:48 ET | 120 | 1 |
| 10:50 ET | 120 | 1 |
| 10:53 ET | 120 | 1.025 |
| 11:06 ET | 100 | 1 |
| 12:38 ET | 100 | 1 |
| 12:45 ET | 2353 | 1 |
| 01:14 ET | 100 | 1 |
| 01:32 ET | 200 | 1.0495 |
| 01:33 ET | 100 | 1.0061 |
| 01:35 ET | 100 | 1 |
| 01:37 ET | 1184 | 1.047 |
| 02:00 ET | 100 | 1 |
| 02:02 ET | 100 | 1 |
| 02:24 ET | 100 | 1 |
| 02:26 ET | 100 | 1 |
| 02:36 ET | 1000 | 1.025 |
| 02:54 ET | 100 | 1 |
| 03:03 ET | 500 | 1.05 |
| 03:14 ET | 100 | 1 |
| 03:32 ET | 100 | 1 |
| 03:34 ET | 100 | 1 |
| 03:38 ET | 1000 | 1 |
| 03:45 ET | 100 | 1 |
| 03:48 ET | 200 | 1 |
| 03:50 ET | 130 | 1 |
| 03:54 ET | 100 | 1 |
| 03:56 ET | 100 | 1 |
| 03:57 ET | 100 | 1 |
| 03:59 ET | 203 | 1.01 |
Sep 25, 2024
Cyclacel Pharmaceuticals Announces Completion of Enrollment in the Biomarker-Enriched Patient Cohort of Its Phase 2 Study, from 9:15AM ET on Wednesday Sep 25, 2024 by Dow Jones
9:15AM ET on Wednesday Sep 25, 2024 by Dow Jones
Sep 4, 2024
Cyclacel Pharmaceuticals Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference, from 9:15AM ET on Wednesday Sep 04, 2024 by Dow Jones
9:15AM ET on Wednesday Sep 04, 2024 by Dow Jones
Sep 3, 2024
Cyclacel Pharmaceuticals Confirms It Has Filed an Appeal to Nasdaq Staff Delisting Letter, from 9:15AM ET on Tuesday Sep 03, 2024 by Dow Jones
9:15AM ET on Tuesday Sep 03, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Cyclacel Pharmaceuticals Inc | 2.0M | -0.1x | --- |
Peak Bio Inc | 925.0K | -0.9x | --- |
Lipella Pharmaceuticals Inc | 3.2M | -0.8x | --- |
CNBX Pharmaceuticals Inc | 230.2K | -0.2x | --- |
Aditxt Inc | 1.6M | 0.0x | --- |
Herborium Group Inc | 1.1M | 0.0x | --- |
Company Information
Cyclacel Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing cancer medicines based on cell cycle, transcriptional regulation and mitosis control biology. The transcriptional regulation program is evaluating fadraciclib, a Cyclin-dependent kinase 9 (CDK9) inhibitor, in solid tumors and hematological malignancies. The epigenetic/anti-mitotic program is evaluating plogosertib, in solid tumors and hematological malignancies. The Company's Plogosertib is a novel, small molecule, selective and potent Polo-like kinase 1 (PLK1) inhibitor, which has demonstrated potent and selective target inhibition (PLK1 IC50 approximately 3 nM) and efficacy in human tumor xenografts at non-toxic doses. Its translational biology program supports the development of plogosertib in solid tumor and hematological malignancy indications.
Contact Information
- Headquarters
- 200 Connell Dr Ste 1500BERKELEY HEIGHTS, NJ, United States 07922-2811
- Phone
- 908-517-7330
- Fax
- 866-271-3466
Executives
- Independent Chairman of the Board
- Samuel Barker
- President, Chief Executive Officer, Director
- Spiro Rombotis
- Chief Financial Officer, Chief Operating Officer, Executive Vice President - Finance, Secretary, Director
- Paul Mcbarron
- Interim Chief Medical Officer, Director
- Brian Schwartz
- Independent Director
- Kenneth Ferguson
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.0M |
|---|---|
Revenue (TTM) | $80.0K |
Shares Outstanding | 2.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.52 |
EPS | $-16.14 |
Book Value | $0.57 |
P/E Ratio | -0.1x |
Price/Sales (TTM) | 24.9 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -25,255.00% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
